Minirin Melt (Desmopressin)

Desmopressin, the active ingredient in Minirin Melt, is a vasopressin (antidiuretic hormone) analog presented as an oral melt (orodispersible tablet) for oral use. It is indicated for the management of central diabetes insipidus, nocturnal enuresis (bedwetting) and primary nocturnal polyuria in patients who require reduced urine output.

GNH USA supplies Minirin Melt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The company ensures product quality, traceability and compliance with Good Distribution Practice throughout the supply chain.

Desmopressin is employed to treat disorders of water balance that cause excessive urine output by activating renal V2 receptors. - Central diabetes insipidus: concentrates urine and reduces excessive thirst and polyuria, improving fluid balance and stabilizing serum osmolality in affected individuals. - Nocturnal enuresis: lowers nighttime urine production, supporting dry nights for children and adults with bedwetting and reducing the frequency of nighttime awakenings. - Primary nocturnal polyuria: diminishes overnight urine volume, helping patients achieve uninterrupted sleep and may improve quality of life.

Desmopressin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache reported. - Nasal congestion: sensation of stuffiness or runny nose. - Nausea: occasional feeling of queasiness. - Abdominal discomfort: mild stomach pain or cramps. - Hyponatremia (mild): low sodium levels without severe symptoms.

Serious or Rare Side Effects: - Hyponatremia (severe): significant sodium depletion leading to confusion, seizures or coma. - Water intoxication: excessive water retention causing rapid weight gain and edema. - Allergic reaction: rash, itching, swelling or difficulty breathing. - Thromboembolic events: rare clot formation in veins or arteries.

When prescribing Desmopressin, clinicians should consider several precautionary measures to ensure safe use. - Assess fluid balance: evaluate patient’s hydration status before initiating therapy. - Monitor electrolytes: regularly check serum sodium levels during treatment. - Limit fluid intake: advise patients to restrict excessive water consumption while on the drug. - Caution in renal impairment: adjust use in patients with reduced kidney function. - Avoid in uncontrolled hypertension: contraindicated in patients with severe high blood pressure. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Desmopressin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use of thiazide diuretics: may increase risk of hyponatremia. - NSAIDs (e.g., ibuprofen, naproxen): can potentiate water retention and hyponatremia. - Selective serotonin reuptake inhibitors (SSRIs): heightened risk of severe hyponatremia.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): possible alteration of coagulation parameters. - Antidiuretic hormone antagonists: may reduce therapeutic effect of Desmopressin. - CYP450 inducers (e.g., carbamazepine): may decrease plasma concentration.